Kimberly-Clark prices $4.9B bond sale to fund $36B Kenvue takeover

What's the deal? Kimberly-Clark has priced a $4.9 billion private offering of senior unsecured notes to help fund its roughly $36 billion acquisition of KenvueDealroom has a profile for this one. Try Dealroom →, the maker of Tylenol and Band-Aid. The notes come in five tranches maturing between 2028 and 2036, with coupons ranging from 5.100% to 5.800%.

Why now? The offering advances toward an expected fourth-quarter close of the Kenvue deal, announced last year. JPMorgan supplied a $7.7 billion bridge facility to back the acquisition; the new notes are intended to refinance part of that short-term borrowing.

What's the endgame? The tie-up would combine Kimberly-Clark's household and personal-care products with Kenvue's consumer-health brands, including Neutrogena, Listerine, and Benadryl. The companies have said the combined business would generate $32 billion in revenue and rank second in health and wellness, behind Procter & Gamble.

Proceeds, with cash on hand and commercial-paper borrowings, will cover the cash consideration and related costs. Citigroup, JPMorgan, and Morgan Stanley are on the deal; closing is expected October 29, 2026.

What could go wrong? The offering is not conditioned on the acquisition closing. If the deal collapses or is not completed by the outside date, Kimberly-Clark must redeem the notes at 101% of principal plus accrued interest. Kenvue, spun out of Johnson & Johnson in 2023, has faced financial pressure and a dispute with the Trump administration over Tylenol's safety.

The signal: At $4.9 billion, the offering ranks among the largest post-IPO debt raises on record for a US wellness and beauty company — the top of 51 comparable deals. It underscores how Kimberly-Clark is leaning on debt markets, rather than equity, to finance a deal that would reshape the consumer-health sector.

Read more: pr.lakeoconeebreeze.net

Image credit: Governo do Estado de São Paulo